At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 81 enrolled
Drug / intervention
pegaptanib sodium (Macugen)drug
Likely dose
pegaptanib sodium (Macugen) 0.3 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Open-Label Multi Center Trial Evaluating The Safety And Efficacy Of 0.3 Mg/Eye Pegaptanib Sodium (Macugen) Intravitreous Injection Given Every 6 Weeks For 54 Weeks In Patients With Small Neovascular Age-Related Macular Degeneration (AMD) Lesions
In Brief
A Phase 4 clinical trial evaluating pegaptanib sodium (Macugen) for Macular Degeneration. Completed, enrolled 81 participants across 34 sites.
Detailed Summary
To evaluate the efficacy, based on the best-corrected visual acuity (using the ETDRS chart), of a 0.3 mg/eye pegaptanib sodium intravitreous injection given every 6 weeks for 54 weeks in patients with exudative age-related macular degeneration and evidence of recent onset, subfoveal and/or juxtafoveal choroidal neovascularization.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration
CountriesFrance
CollaboratorsITEC GROUP 3
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2006
Enrollment StartJul 2006
Primary CompletionAug 2008
TodayJul 2026
First PostedMay 10, 2006
Enrollment StartJul 1, 2006
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 20.1 years ago
Interventions
pegaptanib sodium (Macugen)drug
0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks.